Publications
- Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
Aiello TF, Salmanton-Garcia J, Marchesi F, et al.
Haematologica. 2024 Aug 1;109(8):2693-2700.
- Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Lahmer T, Salmanton-García J, Marchesi F, et al.
Infection. 2024 Jun;52(3):1125-1141.
- Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
Salmanton-García J, Marchesi F, Farina F, et al.
EClinicalMedicine. 2024 Mar 18;71:102553.
- The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey
El-Ashwah S, Salmanton-García J, Bilgin YM, et al.
Leuk Lymphoma. 2024 Feb;65(2):199-208.
- Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry
Musto P, Salmanton-García J, Sgherza N, et al.
Hematol Oncol 2024; 42(1): e3240.
- Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
Rossi G, Salmanton-García J, Cattaneo C, et al.
Int J Infect Dis 2023; 137: 98-110.
- Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients
Salmanton-García J, Marchesi F, Itri F, et al.
Hemasphere 2023; 7(11): e970.
- Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry
Salmanton-García J, Marchesi F, Koehler P, et al.
Int J Antimicrob Agents 2023; 62(4): 106952.
- SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report
Criscuolo M, Salmanton-García J, Fracchiolla N, et al.
J Investig Allergol Clin Immunol 2023; 33(3): 225-7.
- Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
van Doesum JA, Salmanton-García J, Marchesi F, et al.
Blood Adv 2023; 7(11): 2645-55.
- Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
Salmanton-García J, Marchesi F, Gomes da Silva M, et al.
EClinicalMedicine 2023; 58: 101939.
- Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
Marchesi F, Salmanton-García J, Buquicchio C, et al.
J Hematol Oncol 2023; 16(1): 32.
- Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry
Marchetti M, Salmanton-García J, El-Ashwah S, et al.
Ther Adv Hematol 2023; 14: 20406207231154706.
- Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
Busca A, Salmanton-García J, Marchesi F, et al.
Front Immunol 2023; 14: 1125030.
- COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
Marchesi F, Salmanton-García J, Emarah Z, et al.
Haematologica 2023; 108(1): 22-33.
- Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Pagano L, Salmanton-García J, Marchesi F, et al.
Blood. 2022 Dec 29;140(26):2773-2787.
- Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
Cattaneo C, Salmanton-García J, Marchesi F, et al.
Cancers (Basel). 2022 Nov 10;14(22):5530.
- Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report
Salmanton-García J, Marchesi F, Glenthøj A, et al.
Hemasphere. 2022 Oct 25;6(11):e789.
- B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Infante MS, Salmanton-García J, Fernández-Cruz A, et al.
Front Oncol. 2022 Oct 3;12:992137.
- Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
Blennow O, Salmanton-García J, Nowak P, et al.
Am J Hematol. 2022 Aug;97(8):E312-E317.
- COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey
Lamure S, Salmanton-García J, Robin-Marieton E, et al.
Blood Adv. 2022 Jul 12;6(13):3870-3874.
- COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Busca A, Salmanton-García J, Corradini P, et al.
Blood Adv. 2022 Apr 12;6(7):2427-2433.
- COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Pagano L, Salmanton-García J, Marchesi F, et al.
Blood. 2022 Mar 10;139(10):1588-1592.
- COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Pagano L, Salmanton-García J, Marchesi F, et al.
J Hematol Oncol. 2021 Oct 14;14(1):168.
- EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19
Salmanton-García J, Busca A, Cornely OA, et al.
Hemasphere. 2021 Jun 25;5(7):e612.
Back